Protein / target
Trifunctional purine biosynthetic protein adenosine-3
Protein at a glance
Biological role
Phosphoribosylformylglycinamidine cyclo-ligase activity
Primary system
Nervous system
Strongest disease association
non-small cell lung carcinoma
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
5 approved · 1 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Trifunctional enzyme that catalyzes three distinct reactions as part of the 'de novo' inosine monophosphate biosynthetic pathway
Domains and Gene Ontology detail (18)Hide
Domains & features
Gene Ontology
- Ccytosol
- Cextracellular exosome
- FATP binding
- Fmetal ion binding
- Fphosphoribosylamine-glycine ligase activity
- Fphosphoribosylformylglycinamidine cyclo-ligase activity
- Fphosphoribosylglycinamide formyltransferase activity
- P'de novo' AMP biosynthetic process
- P'de novo' IMP biosynthetic process
- P'de novo' XMP biosynthetic process
- Padenine biosynthetic process
- Pbrainstem development
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Metabolic enzyme activity
- ·phosphoribosylglycinamide formyltransferase activity
View underlying pathways (1)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
GAR transformylase inhibitor
Appears in clinical studies involving malignant pleural mesothelioma, mesothelioma, non-small cell lung carcinoma, neoplasm
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 281 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 6 total
non-small cell lung carcinoma · non-small cell lung carcinoma · malignant pleural mesothelioma
mesothelioma · non-small cell lung carcinoma
colorectal cancer · non-small cell lung carcinoma
lung large cell carcinoma · adenocarcinoma · mesothelioma
lung large cell carcinoma
malignant pleural mesothelioma · mesothelioma · non-small cell lung carcinoma
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Withdrawn from market
Market withdrawal: Pemetrexed Sandoz (EMA)
- New publicationPhase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
- Withdrawn from market
Market withdrawal: Ciambra (EMA)
- New publicationPembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
- New publicationAtezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
- New publicationOsimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
- Regulatory approval
Approval: Pemetrexed Fresenius Kabi (EMA)
- Regulatory approval
Approval: Armisarte (previously Pemetrexed Actavis) (EMA)
- Regulatory approval
Approval: Pemetrexed Accord (EMA)
- Regulatory approval
Approval: Pemetrexed medac (EMA)
- Regulatory approval
Approval: Pemetrexed Pfizer (previously Pemetrexed Hospira) (EMA)
- New publicationFirst-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.